Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
Add more filters










Publication year range
2.
Clin Exp Immunol ; 204(1): 96-106, 2021 04.
Article in English | MEDLINE | ID: mdl-33346915

ABSTRACT

A clearer understanding of the tumor immune microenvironment (TIME) in metastatic clear cell renal cell carcinoma (ccRCC) may help to inform precision treatment strategies. We sought to identify clinically meaningful TIME signatures in ccRCC. We studied tumors from 39 patients with metastatic ccRCC using quantitative multiplexed immunofluorescence and relevant immune marker panels. Cell densities were analyzed in three regions of interest (ROIs): tumor core, tumor-stroma interface and stroma. Patients were stratified into low- and high-marker density groups using median values as thresholds. Log-rank and Cox regression analyses while controlling for clinical variables were used to compare survival outcomes to patterns of immune cell distributions. There were significant associations with increased macrophage (CD68+ CD163+ CD206+ ) density and poor outcomes across multiple ROIs in primary and metastatic tumors. In primary tumors, T-bet+ T helper type 1 (Th1) cell density was highest at the tumor-stromal interface (P = 0·0021), and increased co-expression of CD3 and T-bet was associated with improved overall survival (P = 0·015) and survival after immunotherapy (P = 0·014). In metastatic tumor samples, decreased forkhead box protein 3 (FoxP3)+ T regulatory cell density correlated with improved survival after immunotherapy (P = 0·016). Increased macrophage markers and decreased Th1 T cell markers within the TIME correlated with poor overall survival and treatment outcomes. Immune markers such as FoxP3 showed consistent levels across the TIME, whereas others, such as T-bet, demonstrated significant variance across the distinct ROIs. These findings suggest that TIME profiling outside the tumor core may identify clinically relevant associations for patients with metastatic ccRCC.


Subject(s)
Carcinoma, Renal Cell/therapy , Immunotherapy/methods , Kidney Neoplasms/therapy , Tumor Microenvironment/immunology , Adult , Aged , Biomarkers, Tumor/immunology , Biomarkers, Tumor/metabolism , Carcinoma, Renal Cell/immunology , Carcinoma, Renal Cell/metabolism , Female , Humans , Immune System/immunology , Immune System/metabolism , Immune System/pathology , Kaplan-Meier Estimate , Kidney Neoplasms/immunology , Kidney Neoplasms/metabolism , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/metabolism , Lymphocytes, Tumor-Infiltrating/pathology , Macrophages/immunology , Macrophages/metabolism , Macrophages/pathology , Male , Middle Aged , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocyte Subsets/pathology , Treatment Outcome
3.
Oncogene ; 36(31): 4498-4507, 2017 08.
Article in English | MEDLINE | ID: mdl-28368420

ABSTRACT

Parathyroid hormone-related protein (PTHrP) is a critical regulator of bone resorption and augments osteolysis in skeletal malignancies. Here we report that the mature PTHrP1-36 hormone is processed by matrix metalloproteinases to yield a stable product, PTHrP1-17. PTHrP1-17 retains the ability to signal through PTH1R to induce calcium flux and ERK phosphorylation but not cyclic AMP production or CREB phosphorylation. Notably, PTHrP1-17 promotes osteoblast migration and mineralization in vitro, and systemic administration of PTHrP1-17 augments ectopic bone formation in vivo. Further, in contrast to PTHrP1-36, PTHrP1-17 does not affect osteoclast formation/function in vitro or in vivo. Finally, immunoprecipitation-mass spectrometry analyses using PTHrP1-17-specific antibodies establish that PTHrP1-17 is indeed generated by cancer cells. Thus, matrix metalloproteinase-directed processing of PTHrP disables the osteolytic functions of the mature hormone to promote osteogenesis, indicating important roles for this circuit in bone remodelling in normal and disease contexts.


Subject(s)
Matrix Metalloproteinases/physiology , Osteogenesis , Parathyroid Hormone-Related Protein/physiology , Animals , Bone Resorption/etiology , Cell Differentiation , Cell Line , Cell Movement , Female , Humans , Mice , Osteoblasts/cytology , Osteoblasts/physiology
4.
Annu Rev Food Sci Technol ; 7: 439-56, 2016.
Article in English | MEDLINE | ID: mdl-26772414

ABSTRACT

This review elucidates the state-of-the-art knowledge about pathogen population heterogeneity and describes the genotypic and phenotypic analyses of persister subpopulations and stress-resistant variants. The molecular mechanisms underlying the generation of persister phenotypes and genetic variants are identified. Zooming in on Listeria monocytogenes, a comparative whole-genome sequence analysis of wild types and variants that enabled the identification of mutations in variants obtained after a single exposure to lethal food-relevant stresses is described. Genotypic and phenotypic features are compared to those for persistent strains isolated from food processing environments. Inactivation kinetics, models used for fitting, and the concept of kinetic modeling-based schemes for detection of variants are presented. Furthermore, robustness and fitness parameters of L. monocytogenes wild type and variants are used to model their performance in food chains. Finally, the impact of stress-resistant variants and persistence in food processing environments on food safety is discussed.


Subject(s)
Food Microbiology , Food Safety , Listeria monocytogenes , Food Handling/instrumentation , Food Handling/methods , Foodborne Diseases/microbiology , Foodborne Diseases/prevention & control , Genotype , Humans , Listeria monocytogenes/classification , Listeria monocytogenes/genetics , Listeria monocytogenes/physiology , Models, Biological , Mutation , Phenotype , Stress, Physiological
5.
Oncogene ; 35(21): 2723-34, 2016 05.
Article in English | MEDLINE | ID: mdl-26387544

ABSTRACT

Multiple myeloma (MM) remains an incurable malignancy due, in part, to the influence of the bone marrow microenvironment on survival and drug response. Identification of microenvironment-specific survival signaling determinants is critical for the rational design of therapy and elimination of MM. Previously, we have shown that collaborative signaling between ß1 integrin-mediated adhesion to fibronectin and interleukin-6 confers a more malignant phenotype via amplification of signal transducer and activator of transcription 3 (STAT3) activation. Further characterization of the events modulated under these conditions with quantitative phosphotyrosine profiling identified 193 differentially phosphorylated peptides. Seventy-seven phosphorylations were upregulated upon adhesion, including PYK2/FAK2, Paxillin, CASL and p130CAS consistent with focal adhesion (FA) formation. We hypothesized that the collaborative signaling between ß1 integrin and gp130 (IL-6 beta receptor, IL-6 signal transducer) was mediated by FA formation and proline-rich tyrosine kinase 2 (PYK2) activity. Both pharmacological and molecular targeting of PYK2 attenuated the amplification of STAT3 phosphorylation under co-stimulatory conditions. Co-culture of MM cells with patient bone marrow stromal cells (BMSC) showed similar ß1 integrin-specific enhancement of PYK2 and STAT3 signaling. Molecular and pharmacological targeting of PYK2 specifically induced cell death and reduced clonogenic growth in BMSC-adherent myeloma cell lines, aldehyde dehydrogenase-positive MM cancer stem cells and patient specimens. Finally, PYK2 inhibition similarly attenuated MM progression in vivo. These data identify a novel PYK2-mediated survival pathway in MM cells and MM cancer stem cells within the context of microenvironmental cues, providing preclinical support for the use of the clinical stage FAK/PYK2 inhibitors for treatment of MM, especially in a minimal residual disease setting.


Subject(s)
Focal Adhesion Kinase 2/metabolism , Multiple Myeloma/pathology , Animals , Cell Death/physiology , Cell Line, Tumor , Female , Focal Adhesion Kinase 2/antagonists & inhibitors , Humans , Interleukin-6/metabolism , Janus Kinase 1/metabolism , Mice , Mice, Inbred C57BL , Molecular Targeted Therapy , Multiple Myeloma/drug therapy , Multiple Myeloma/genetics , Multiple Myeloma/metabolism , Phosphorylation , Protein Kinase Inhibitors/pharmacology , STAT3 Transcription Factor/metabolism , Signal Transduction , Tumor Microenvironment
6.
Oncogene ; 35(10): 1225-35, 2016 Mar 10.
Article in English | MEDLINE | ID: mdl-26073081

ABSTRACT

The mechanisms by which some melanoma cells adapt to Serine/threonine-protein kinase B-Raf (BRAF) inhibitor therapy are incompletely understood. In the present study, we used mass spectrometry-based phosphoproteomics to determine how BRAF inhibition remodeled the signaling network of melanoma cell lines that were BRAF mutant and PTEN null. Short-term BRAF inhibition was associated with marked changes in fibronectin-based adhesion signaling that were PTEN dependent. These effects were recapitulated through BRAF siRNA knockdown and following treatment with chemotherapeutic drugs. Increased fibronectin expression was also observed in mouse xenograft models as well as specimens from melanoma patients undergoing BRAF inhibitor treatment. Analysis of a melanoma tissue microarray showed loss of PTEN expression to predict for a lower overall survival, with a trend for even lower survival being seen when loss of fibronectin was included in the analysis. Mechanistically, the induction of fibronectin limited the responses of these PTEN-null melanoma cell lines to vemurafenib, with enhanced cytotoxicity observed following the knockdown of either fibronectin or its receptor α5ß1 integrin. This in turn abrogated the cytotoxic response to BRAF inhibition via increased AKT signaling, which prevented the induction of cell death by maintaining the expression of the pro-survival protein Mcl-1. The protection conveyed by the induction of FN expression could be overcome through combined treatment with a BRAF and PI3K inhibitor.


Subject(s)
Fibronectins/metabolism , Melanoma/pathology , PTEN Phosphohydrolase/deficiency , PTEN Phosphohydrolase/genetics , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , Animals , Cell Line, Tumor , Cell Survival/drug effects , Female , Gene Expression Regulation, Neoplastic/drug effects , Gene Knockdown Techniques , Humans , Integrin alpha5beta1/metabolism , Mice , Myeloid Cell Leukemia Sequence 1 Protein/metabolism , Proteomics , Proto-Oncogene Proteins B-raf/deficiency , RNA, Small Interfering/genetics , Signal Transduction/drug effects , Xenograft Model Antitumor Assays
7.
Oncogene ; 33(42): 4985-96, 2014 Oct 16.
Article in English | MEDLINE | ID: mdl-24166501

ABSTRACT

Despite the clinical success of tamoxifen, its resistance remains a major challenge in breast cancer. Here we show that Aurora-A determines tamoxifen sensitivity by regulation of oestrogen receptor (ER)α. Ectopic expression of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivity in ERα-positive breast cancer. Elevated Aurora-A was significantly associated with the recurrence of ERα-positive tumours. Notably, Aurora-A inhibitor MLN8237, which is currently in clinical trial, synergizes with tamoxifen and overcomes tamoxifen resistance. Furthermore, Aurora-A interacts with and phosphorylates ERα on serine-167 and -305, leading to increase in ERα DNA-binding and transcriptional activity. Elevated levels of Aurora-A are significantly associated with disease-free survival in ERα-positive but not ERα-negative breast cancers. These data suggest that Aurora-A has a pivotal role in tamoxifen resistance and ERα is a bona fide substrate of Aurora-A. Thus, Aurora-A represents a prognostic marker in ERα-positive tumour and a critical therapeutic target in tamoxifen-resistant breast cancer, and Aurora-A inhibitor could be used as either an independent or concurrent agent in tamoxifen-resistant tumour.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Aurora Kinase A/physiology , Breast Neoplasms/enzymology , Estrogen Receptor alpha/metabolism , Protein Processing, Post-Translational , Tamoxifen/pharmacology , Animals , Aurora Kinase A/antagonists & inhibitors , Azepines/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Cell Line, Tumor , Cyclin D1/genetics , Cyclin D1/metabolism , Disease-Free Survival , Drug Resistance, Neoplasm , Drug Synergism , Female , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Humans , Kaplan-Meier Estimate , Mice, Nude , Phosphorylation , Proportional Hazards Models , Pyrimidines/pharmacology , Transcriptional Activation , Xenograft Model Antitumor Assays
8.
Br J Cancer ; 109(9): 2378-88, 2013 Oct 29.
Article in English | MEDLINE | ID: mdl-24104967

ABSTRACT

BACKGROUND: In cycling tumour cells, the binary cyclin-dependent kinase Cdk4/cyclin D or Cdk2/cyclin E complex is inhibited by p21 following DNA damage to induce G1 cell-cycle arrest. However, it is not known whether other proteins are also recruited within Cdk complexes, or their role, and this was investigated. METHODS: Ovarian A2780 tumour cells were exposed to the platinum-based antitumour agent 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) (DAP), which preferentially induces G1 arrest in a p21-dependent manner. The Cdk complexes were analysed by gel filtration chromatography, immunoblot and mass spectrometry. RESULTS: The active forms of Cdk4 and Cdk2 complexes in control tumour cells have a molecular size of ~140 kDa, which increased to ~290 kDa when inhibited following G1 checkpoint activation by DAP. Proteomic analysis identified Cdk, cyclin, p21 and proliferating cell nuclear antigen (PCNA) in the inhibited complex, and biochemical studies provided unequivocal evidence that the increase in ~150 kDa of the inhibited complex is consistent with p21-dependent recruitment of PCNA as a trimer, likely bound to three molecules of p21. Although p21 alone was sufficient to inhibit the Cdk complex, PCNA was critical for stabilising p21. CONCLUSION: G1 Cdk complexes inhibited by p21 also recruit PCNA, which inhibits degradation and, thereby, prolongs activity of p21 within the complex.


Subject(s)
Cyclin-Dependent Kinase 2/genetics , Cyclin-Dependent Kinase 4/genetics , DNA Damage , G1 Phase/drug effects , Organoplatinum Compounds/pharmacology , Proliferating Cell Nuclear Antigen/metabolism , Antineoplastic Agents/pharmacology , Cell Cycle Checkpoints/drug effects , Cell Cycle Checkpoints/genetics , Cyclin D/genetics , Cyclin D/metabolism , Cyclin E/genetics , Cyclin E/metabolism , Cyclin-Dependent Kinase 2/antagonists & inhibitors , Cyclin-Dependent Kinase 2/metabolism , Cyclin-Dependent Kinase 4/antagonists & inhibitors , Cyclin-Dependent Kinase 4/metabolism , G1 Phase/genetics , HCT116 Cells , Humans , MCF-7 Cells , Proliferating Cell Nuclear Antigen/genetics , Proteomics , Tumor Cells, Cultured
9.
Br J Cancer ; 95(11): 1514-24, 2006 Dec 04.
Article in English | MEDLINE | ID: mdl-17088910

ABSTRACT

The cisplatin analogue 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) (DAP) is a DNA-damaging agent that will be entering clinical trials for its potent cytotoxic effects against cisplatin-resistant tumour cells. This cytotoxicity may reside in its ability to selectively activate G1-phase checkpoint response by inhibiting CDKs via the p53/p21 pathway. We have now evaluated the role of another CDK inhibitor p27 as a contributor to DAP-mediated inhibition of G1-phase CDK2 activity. Our studies in ovarian A2780 tumour cells demonstrate that p27 levels induced by DAP are comparable to or greater than those seen for p21. The induction of p27 is not through a transcriptional mechanism, but rather is due to a four-fold increase in protein stabilisation through a mechanism dependent on p21. Moreover, DAP-induced p21 promoted the selective increase of p27 in the CDK2 complex, but not in CDK4 complex, and this selective increase contributed to inhibition of the CDK2 kinase activity. The inhibited complex contained either p27 or p21, but not both, with the relative levels of cyclin E associated with p27 and p21 indicating that about 25% of the inhibition of CDK2 activity was due to p27 and 75% due to p21. This study provides the first evidence that p27 upregulation is directly attributable to activation of the p53/p21 pathway by a DNA-damaging agent, and promulgates p53/p21/p27 axis as a significant component of checkpoint response.


Subject(s)
Antineoplastic Agents/pharmacology , Cisplatin/analogs & derivatives , Cyclin E/drug effects , Cyclin-Dependent Kinase 2/drug effects , Cyclin-Dependent Kinase Inhibitor p21/drug effects , DNA Damage , Proliferating Cell Nuclear Antigen/drug effects , Blotting, Northern , Cell Line, Tumor , Cisplatin/pharmacology , Cyclin E/metabolism , Cyclin-Dependent Kinase 2/metabolism , Cyclin-Dependent Kinase Inhibitor p21/biosynthesis , Cyclin-Dependent Kinases/drug effects , Cyclin-Dependent Kinases/metabolism , Female , Humans , Immunoblotting , Immunoprecipitation , Organoplatinum Compounds , Plasmids , Proliferating Cell Nuclear Antigen/metabolism , RNA, Small Interfering , Transfection , Up-Regulation
11.
J Mass Spectrom ; 35(8): 1025-34, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10973002

ABSTRACT

The changes in the ion signals in the isotope cluster, mass resolution, signal-to-noise ratio and mass accuracy for matrix-assisted laser desorption/ionization (MALDI) of DNA oligonucleotides (dGGATC, dCAGCt, and dAACCGTT) and their fragment ions were evaluated, and these data were compared with those obtained using 3-hydroxypicolinic acid. Mass spectra obtained by using 2,5-dihydroxybenzoic acid (2,5-DHB) appear to have differences from the theoretical isotopic clusters, which arise by reductive hydrogenation producing a second peak at the M + 2 isotope of the native oligonucleotide. Based on the patterns of the isotopic envelope observed in the in-source decay fragments, we propose that cytosine is the site of reduction. We do not find evidence of reduction of oligonucleotides, viz. dTGGGGTT, that do not contain cytosine; however, 2'-deoxycytidine and 2'-deoxycytidine-5'-monophosphate undergo reductive hydrogenation. Several experiments were carried out in an effort to determine whether the reductive hydrogenation occurs during sample preparation or as a result of laser irradiation. The results of these experiments suggest that it occurs during sample preparation. The relative intensities of ion signals corresponding to the reduced base can be altered by using different matrix additives (aminonaphthalenes) or a different substrate (copper). Also, the oxidized form of 2,5-DHB is trapped by reaction with the side chain of cysteine in glutathione, providing evidence that the reaction occurs in solution as the matrix crystallizes.


Subject(s)
Gentisates , Oligodeoxyribonucleotides/chemistry , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Base Sequence , Cytosine/chemistry , DNA/chemistry , Hydroxybenzoates , Oxidation-Reduction , Picolinic Acids , Ultraviolet Rays
12.
Anal Chem ; 72(16): 3860-6, 2000 Aug 15.
Article in English | MEDLINE | ID: mdl-10959974

ABSTRACT

DNA analysis by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry is hindered by two processes: alkali metal adduction and fragmentation of the intact ionized molecule. The adverse effects of both processes can be reduced by adding ammonium ion salts or compounds such as fructose to the sample preparations. Matrix additives improve sensitivity and resolution of DNA analysis by MALDI. In addition, spot-to-spot reproducibility, resolution, and mass accuracy for DNA oligonucleotides (< or = 12 mer) can be improved by the use of overlayer sample preparations with matrixes that have low aqueous solubilities, such as alpha-cyano-4-hydroxycinnamic acid, ferulic acid, and 2,4,6-trihydroxyacetophenone. For example, resolution for 5-12-mer oligonucleotides is greater than 7000 using overlayer matrix preparations and mass accuracy values are well below 20 ppm. In addition to these methods, a new method for analyzing DNA in positive ion mode is reported using acidified 3-hydroxypicolinic acid. This method does not lose sensitivity for higher mass oligonucleotides as quickly as overlayer methods, and spectra retain > 6000 resolution and mass accuracies of approximately 20 ppm between different overlayer depositions.


Subject(s)
DNA/chemistry , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Reproducibility of Results , Spectrometry, Fluorescence
13.
J Mol Biol ; 298(5): 895-901, 2000 May 19.
Article in English | MEDLINE | ID: mdl-10801356

ABSTRACT

The South American imported fire ant (Solenopsis invicta), without natural enemies in the United States, widely infests the southern United States, causing more than a half billion dollars in health and agriculture-related damage annually in Texas alone. Fire ants are resistant to most insecticides, so control will require a more fundamental understanding of their biochemistry and metabolism leading to the design of selective, ecologically safe insecticides. The 4th instar larvae play a crucial role in the nutrition of the colony by secreting proteinases (especially chymotrypsin) which digest food products for the entire colony. The first structure of an ant proteolytic enzyme, fire ant chymotrypsin, was determined to atomic resolution (1.7 A). A structural comparison of the ant and mammalian structures confirms the "universality" of the serine proteinase motif and reveals a difference at residues 147-148, which are proteolytically removed in the bovine enzyme but are firmly intact in the ant chymotrypsin, suggesting a different activation mechanism for the latter. Likewise, the absence of the covalently attached propeptide domain (1-15) further suggests an uncharacteristic activation mechanism. The presence of Gly189 in the S1 site is an atypical feature of this chymotrypsin and is comparable only to human leukocyte elastase, hornet chymotrypsin and fiddler crab collagenase. Binding studies confirm the chymotrypsin nature of this novel enzyme.


Subject(s)
Ants/enzymology , Chymotrypsin/chemistry , Insect Proteins/chemistry , Amino Acid Sequence , Animals , Binding Sites , Chymotrypsin/metabolism , Crystallography, X-Ray , Disulfides/metabolism , Drug Design , Enzyme Activation , Hydrogen Bonding , Insect Proteins/metabolism , Models, Molecular , Molecular Sequence Data , Protein Structure, Secondary , Sequence Alignment , Structure-Activity Relationship , Substrate Specificity , Water/metabolism
14.
J Mass Spectrom ; 35(2): 258-64, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10679989

ABSTRACT

Laser desorption/ionization mass spectrometry (LDI-MS) has been used to assess the potential of using surrogate markers, bound to cellular structures containing nucleic acids, to image or map the position of these structures within biological samples. In this study, organic dyes were used as markers because of their established use in the histochemical marking of nucleic acids, and also because they are amenable to LDI-MS. Eight cationic dyes were tested and all could be desorbed from nucleic acid samples without additional matrix after specifically binding to these molecules. Methylene Blue was the best of these based on its sensitivity to detection by LDI-MS and the fact that it can be washed from the tissue in areas where it was not specifically bound to provide low-intensity background signals. Experiments are reported which characterize the M(+) ion signal obtained from Methylene Blue with regard to sensitivity, reproducibility and possible use for quantitation. This dye was used to map (with a lateral resolution of 25 microm) several nucleic acid-containing samples spotted on prepared surfaces, and to image the location of nucleic acids in two model tissues, retinal vertical sections and thyroid whole mount sections.


Subject(s)
Cells/chemistry , Animals , Biomarkers , Coloring Agents/chemistry , DNA/chemistry , Methylene Blue/chemistry , Microscopy, Fluorescence , Nucleic Acids/analysis , Rabbits , Rats , Retina/chemistry , Retina/cytology , Saccharomyces cerevisiae/chemistry , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Thyroid Gland/chemistry , Thyroid Gland/cytology
15.
Life Sci ; 58(3): 195-208, 1996.
Article in English | MEDLINE | ID: mdl-9499160

ABSTRACT

Ro41-0960 is a potent, fluorine containing COMT inhibitor which has be en reported to cross the blood brain barrier and to inhibit COMT in the brain. It is structurally similar to Ro40-7592 which is currently undergoing clinical trials in Parkinson's disease. Positron emission tomographic (PET) studies in baboon using F-18 labeled Ro41-0960 demonstrated a negligible uptake in the brain both at tracer doses and with the addition of unlabeled drug (1.5 mg/kg) at all times through a 90 min experimental interval. The brain to plasma ratios of F-18 averaged about 0.025. Region of interest analysis of the brain tissue area suggests that most of F-18 in the brain was due to the blood in the brain and not the brain tissue itself. However, high uptake was observed in the kidneys and in other organs which are known to have high COMT activity. Studies in mice showed that at 30 min after injection of tracer, F-18 in kidneys was largely as unchanged [18F]Ro41-0960 and that it could be displaced with unlabeled Ro41-0960. The fact that the average brain to blood ratio for mice (n=12) was 0.04, and that similar HPLC metabolite patterns were observed for brain and blood, provides consistent evidence that nearly all the F-18 in the brain represents F-18 in the cerebral blood vessels. These studies raise the question of whether the central pharmacological effects of Ro41-0960 are due to its presence in the brain. They also provide the first example of a positron emitter labeled radiotracer for COMT, and provide initial encouraging evidence that [18F]Ro41-0960 may be used to examine COMT in peripheral organs in vivo.


Subject(s)
Benzophenones/metabolism , Catechol O-Methyltransferase/metabolism , Animals , Chromatography, High Pressure Liquid , Female , Fluorine Radioisotopes , Mice , Papio , Time Factors , Tomography, Emission-Computed
17.
Basic Res Cardiol ; 82(3): 233-40, 1987.
Article in English | MEDLINE | ID: mdl-3632567

ABSTRACT

The occurrence of arrhythmias was studied in the "calcium-paradox" model in the isolated rat heart. Clear relationships were found between the duration of calcium-free perfusion and (a) the occurrence of calcium-free-induced electrophysiological changes, (b) the incidence and duration of subsequently induced calcium-repletion arrhythmias and (c) mechanical recovery at the end of the repletion period. The first signs of electrophysiological changes (i.e. decreased heart rate, T-wave amplitude and increased PQ-interval) and irreversible loss of myocardial recovery occurred during or after 60-90 s of calcium-free perfusion. The occurrence of calcium-repletion induced ventricular tachycardia parallelled this onset of irreversible cardiac injury. These results suggest that the process of calcium washout and subsequent sudden calcium overloading may play a role as a trigger in the pathogenesis of ventricular arrhythmias.


Subject(s)
Arrhythmias, Cardiac/etiology , Calcium/metabolism , Animals , Arrhythmias, Cardiac/metabolism , Coronary Circulation , Coronary Disease/complications , Male , Myocardial Contraction , Myocardium/metabolism , Rats , Rats, Inbred Strains , Tachycardia/etiology
18.
J Pharm Pharmacol ; 38(4): 277-82, 1986 Apr.
Article in English | MEDLINE | ID: mdl-2872291

ABSTRACT

Doxorubicin induces an acute cardiotoxicity that becomes manifest in isolated hearts as a deterioration in mechanical function. The oxidative component in this myocardial damage has been investigated. The effects of doxorubicin on the activity of superoxide dismutase and the capacity of the glutathione system, factors of the cellular protective mechanism against free radicals, were examined in rat isolated heart. Doxorubicin was found to reduce the capacity of the protective mechanisms. Whether oxidative membrane damage due to excessive free radical formation plays a role in the pathogenesis of the acute cardiotoxic action of doxorubicin was also examined. Its acute effect on myocardial contraction amplitude, frequency of beating, coronary flow and on the above mentioned biochemical parameters was compared in rat hearts sufficient or deficient in vitamin E. Peroxidation of lipids was measured as the formation of malondialdehyde, one of the final products of this process. Vitamin E deficiency neither aggravated the decrease in the capacity of the cellular protective factors nor worsened the reduction in myocardial function. Nor did induction of lipid peroxidation by doxorubicin occur in vitamin E-deficient hearts. It was concluded that lipid peroxidative damage most probably is not decisive in the development of the acute cardiomyopathy in rats.


Subject(s)
Doxorubicin/toxicity , Heart/drug effects , Lipid Peroxides/biosynthesis , Myocardium/metabolism , Animals , Coronary Circulation/drug effects , Glutathione/metabolism , Glutathione Peroxidase/metabolism , Heart Rate/drug effects , In Vitro Techniques , Male , Malondialdehyde/metabolism , Myocardial Contraction/drug effects , Myocardium/enzymology , Rats , Rats, Inbred Strains , Superoxide Dismutase/metabolism , Vitamin E Deficiency/physiopathology
19.
Life Sci ; 35(12): 1281-8, 1984 Sep 17.
Article in English | MEDLINE | ID: mdl-6482652

ABSTRACT

Excessive formation of free radicals possibly plays an important role in the origin of irreversible damage of the heart after hypoxic, ischemic or Ca2+-free treatment. The effect of these treatments on the activity of superoxide dismutase and the glutathione system was studied on isolated rat heart. These activities reflect the protective capacity of the heart against reactive substances. In addition the peroxidation of lipids is determined in the treated hearts using malondialdehyde formation as an indicator. All experiments were performed using a Langendorff-apparatus with recirculating perfusion. The observed changes in the components of the glutathione system and superoxide dismutase activity both after hypoxic, ischemic and Ca2+-free perfusion, as measured upon reperfusion, indicate a decrease in cellular defense mechanisms in the heart against free radicals. The effect was most pronounced upon Ca2+-repletion after a period of Ca2+-free perfusion. No malondialdehyde could however be detected either in the tissue of the treated hearts or in the perfusate. Our data give reason to expect beneficial effects of an adequate pharmacological treatment, which replenishes the cellular defence systems.


Subject(s)
Calcium/deficiency , Coronary Disease/metabolism , Free Radicals , Hypoxia/metabolism , Myocardium/metabolism , Animals , Benzene Derivatives/pharmacology , Glutathione/metabolism , Heart/drug effects , In Vitro Techniques , Kinetics , Lipid Peroxides/metabolism , Male , Malondialdehyde/metabolism , Perfusion , Rats , Superoxide Dismutase/metabolism
20.
Naunyn Schmiedebergs Arch Pharmacol ; 326(1): 87-9, 1984 May.
Article in English | MEDLINE | ID: mdl-6472488

ABSTRACT

Vitamin E is known to play an important role in the protective capacity of tissues as a free radical scavenger. Rats were made deficient in vitamin E, in order to demonstrate more clearly the formation of free radicals after exposing the rat heart to sudden changes in calcium homeostasis. The formation of malondialdehyde was taken as measure for lipid peroxidation. Malondialdehyde was detected in appreciable amounts both in heart tissue and coronary perfusate of vitamin E-deficient rat hearts after exposing them to the sudden changes in calcium concentration as seen during the calcium paradox. These findings emphasize a the hearts of normally fed rats no malondialdehyde could be detected in tissue or coronary perfusate after the calcium paradox. Therefore an essential role for vitamin E against oxidative stress in heart tissue is also indicated.


Subject(s)
Calcium/metabolism , Lipid Peroxides/metabolism , Myocardium/metabolism , Vitamin E Deficiency/metabolism , Animals , Male , Malondialdehyde/metabolism , Rats , Rats, Inbred Strains
SELECTION OF CITATIONS
SEARCH DETAIL
...